These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1839 related articles for article (PubMed ID: 24909280)
21. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways. Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028 [TBL] [Abstract][Full Text] [Related]
22. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol]. Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117 [TBL] [Abstract][Full Text] [Related]
23. [Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells]. Ren Y; Zha X; Zhang GN Zhonghua Yi Xue Za Zhi; 2007 May; 87(17):1204-6. PubMed ID: 17686243 [TBL] [Abstract][Full Text] [Related]
24. [High D-glucose alters PI3K and Akt signaling and leads to endothelial cell migration, proliferation and angiogenesis dysfunction]. Yu P; Yu DM; Qi JC; Wang J; Zhang QM; Zhang JY; Tang YZ; Xing QL; Li MZ Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3425-30. PubMed ID: 17313857 [TBL] [Abstract][Full Text] [Related]
25. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. McDonald GT; Sullivan R; Paré GC; Graham CH Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Xie X; Tang B; Zhou J; Gao Q; Zhang P Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209 [TBL] [Abstract][Full Text] [Related]
29. [Cyr61 expression influences cancer cell proliferation and apoptosis via PI3K pathway in human ovarian carcinoma cells]. Xiao L; He C; Li X; Chen Y; Zhou JD Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):616-20. PubMed ID: 23141184 [TBL] [Abstract][Full Text] [Related]
30. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways. Chen C; Chang YC; Lan MS; Breslin M Int J Oncol; 2013 Mar; 42(3):1113-9. PubMed ID: 23354006 [TBL] [Abstract][Full Text] [Related]
31. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. MacKeigan JP; Taxman DJ; Hunter D; Earp HS; Graves LM; Ting JP Clin Cancer Res; 2002 Jul; 8(7):2091-9. PubMed ID: 12114408 [TBL] [Abstract][Full Text] [Related]
32. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946 [TBL] [Abstract][Full Text] [Related]
33. [Wogonoside reverses cisplatin resistance in SGC7901/cDDP cells through inhibition of PI3K/Akt/Nrf2/ARE signaling pathway]. Wang LJ; Wang SG; Deng TX Sheng Li Xue Bao; 2018 Aug; 70(4):397-405. PubMed ID: 30112565 [TBL] [Abstract][Full Text] [Related]
34. Equol inhibits proliferation of human gastric carcinoma cells via modulating Akt pathway. Yang ZP; Zhao Y; Huang F; Chen J; Yao YH; Li J; Wu XN World J Gastroenterol; 2015 Sep; 21(36):10385-99. PubMed ID: 26420965 [TBL] [Abstract][Full Text] [Related]
35. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021 [TBL] [Abstract][Full Text] [Related]
36. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression. Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490 [TBL] [Abstract][Full Text] [Related]
37. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway]. Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997 [TBL] [Abstract][Full Text] [Related]
38. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells. Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W Urol Int; 2011; 87(1):105-13. PubMed ID: 21597260 [TBL] [Abstract][Full Text] [Related]
39. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells. Kim SH; Song YC; Kim SH; Jo H; Song YS Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115 [TBL] [Abstract][Full Text] [Related]
40. Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. Dizeyi N; Hedlund P; Bjartell A; Tinzl M; Austild-Taskén K; Abrahamsson PA Urol Oncol; 2011; 29(4):436-45. PubMed ID: 19926313 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]